The quest for suitable conduits for dialysis access has continued since the first patients were dialysed. Whilst synthetic grafts made from expanded polytetrafluoroethylene (ePTFE) have been the main definitive option after autologous arteriovenous fistulas they have a number of drawbacks, which has led to the use and development of biological grafts such as autografts, homografts or xenografts. Technology continues to improve and currently biosynthetic options are available which may combine the benefits of a readily available product without the drawbacks of PTFE. The history and evidence of biological options for haemodialysis access are discussed.
QuintonW., DillardD., ScribnerB.H.. Cannulation of blood vessels for prolonged hemodialysis.Trans Am Soc Artif Intern Organs.1960; 6: 104–113.
2.
ScribnerB.H., BuriR., CanerJ.E.Z., HegstromR., BurnellJ.M.. The treatment of chronic uremia by means of intermittent hemodialysis: a preliminary report.Trans Am Soc Artif Intern Organs.1960; 6: 114–122.
3.
KonnerK.. History of vascular access for haemodialysis.Nephrol Dial Transplant.2005; 20(12): 2629–2635.
4.
PeckM.K., DusserreN., ZagalskiK.. New biological solutions for hemodialysis access.J Vasc Access.2011; 12(3): 185–192.
5.
JamplisR.W., RugtivG.M., BurkmanV., CressmanR.D.. Resection of ruptured abdominal aortic aneurysm with fatal rupture of aortic homograft.Ann Surg.1958; 147(3): 393–398.
6.
JashariR., Van HoeckB., NgakamR., GoffinY., FanY.. Banking of cryopreserved arterial allografts in Europe: 20 years of operation in the European Homograft Bank (EHB) in Brussels.Cell Tissue Bank.2013; 14(4): 589–599.
7.
GalambosB., OláhA., BangaP., CsöngeL., AlmásiJ., AcsádyG.. Successful human vascular reconstructions with long-term refrigerated venous homografts.Eur Surg Res.2009; 43(3): 256–261.
8.
FioreM., LocatiP., MussiC.. Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma.Eur J Surg Oncol.2008; 34(6): 720–724.
9.
MerrillR.H., McLeodC.G.Jr., JarstferB.S.. The use of lyophilized vein grafts in vascular access for chronic hemodialysis.Artif Organs.1979; 3(3): 245–248.
BaraldiA., ManentiA., Di FeliceA.. Absence of rejection in cryopreserved saphenous vein allografts for hemodialysis.ASAIO Trans.1989; 35(3): 196–199.
12.
BenedettoB., LipkowitzG., MaddenR.. Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitization.J Vasc Surg.2001; 34(1): 139–142.
13.
Lopez-CeperoM., SandersC.E., BuggsJ., BowersV.. Sensitization of renal transplant candidates by cryopreserved cadaveric venous or arterial allografts.Transplantation.2002; 73(5): 817–819.
14.
MaddenR.L., LipkowitzG.S., BrowneB.J., KurbanovA.. Experience with cryopreserved cadaveric femoral vein allografts used for hemodialysis access.Ann Vasc Surg.2004; 18(4): 453–458.
15.
MaddenR.L., LipkowitzG.S., BrowneB.J., KurbanovA.. A comparison of cryopreserved vein allografts and prosthetic grafts for hemodialysis access.Ann Vasc Surg.2005; 19(5): 686–691.
16.
BoltonW.D., CullD.L., TaylorS.M.. The use of cryopreserved femoral vein grafts for hemodialysis access in patients at high risk for infection: a word of caution.J Vasc Surg.2002; 36(3): 464–468.
KoennekerS., TeebkenO.E., BonehieM.. A biological alternative to alloplastic grafts in dialysis therapy: evaluation of an autologised bioartificial haemodialysis shunt vessel in a sheep model.Eur J Vasc Endovasc Surg.2010; 40(6): 810–816.
19.
RosenbergN., MartinezA., SawyerP.N., WesolowskiS.A., PostlethwaitR.W., DillonM.L.Jr.. Tanned collagen arterial prosthesis of bovine carotid origin in man. Preliminary studies of enzyme-treated heterografts.Ann Surg.1966; 164(2): 247–256.
OakesD.D., SpeesE.K.Jr., LightJ.A., FlyeM.W.. A three year experience using modified bovine arterial heterografts for vascular access in patients requiring hemodialysis.Ann Surg.1978; 187(4): 423–429.
22.
JohnsonJ.M., KenoyerM.R., JohnsonK.E., PotterD.J., NickasG.M., WilliamsT.. The modified bovine heterograft in vascular access for chronic hemodialysis.Ann Surg.1976; 183(1): 62–66.
KennealeyP.T., EliasN., HertlM.. A prospective, randomized comparison of bovine carotid artery and expanded polytetrafluoroethylene for permanent hemodialysis vascular access.J Vasc Surg.2011; 53(6): 1640–1648.
25.
WidmerM.K., AreggerF., StaufferE.. Intermediate outcome and risk factor assessment of bovine vascular heterografts used as AV-fistulas for hemodialysis access.Eur J Vasc Endovasc Surg.2004; 27: 660–665.
26.
TahamiV.B., HakkiH., ReberP.U., WidmerM.K., KniemeyerH.W.. Polytetrafluoroethylene and bovine mesenterial vein grafts for hemodialysis access: a comparative study.J Vasc Access.2007; 8(1): 17–20.
27.
KatzmanH.E., GlickmanM.H., SchildA.F., FujitaniR.M., LawsonJ.H.. Multicenter evaluation of the bovine mesenteric vein bioprostheses for hemodialysis access in patients with an earlier failed prosthetic graft.J Am Coll Surg.2005; 201(2): 223–230.
28.
BenedettoF., CarellaG., LentiniS.. Use of bovine mesenteric vein in rescue vascular access surgery.J Vasc Access.2010; 11(2): 112–114.
29.
FieldP.L.. The chemically treated bovine ureter—clinical performance of a novel biological vascular prosthesis.Cardiovasc Surg.2003; 11(1): 30–34.
30.
KingstonG.T., DarbyC.R., RobertsI.S.. The pathology of depopulated bovine ureter xenografts utilized for vascular access in haemodialysis patients.Histopathology.2009; 55(2): 154–160.
31.
MatsuuraJ.H., BlackK.S., LevittA.B.. Cellular remodeling of depopulated bovine ureter used as an arteriovenous graft in the canine model.J Am Coll Surg.2004; 198(5): 778–783.
32.
DasN., BratbyM.J., ShrivastavaV.. Results of a seven-year, single-centre experience of the long-term outcomes of bovine ureter grafts used as novel conduits for haemodialysis fistulas.Cardiovasc Intervent Radiol.2011; 34(5): 958–963.
33.
ChemlaE.S., MorsyM.. Randomized clinical trial comparing decellularized bovine ureter with expanded polytetrafluoroethylene for vascular access.Br J Surg.2009; 96(1): 34–39.
34.
SmithM.P., SparkJ.I., PatelJ.V., BorderD.J., OswalD., LewingtonA.J.. Massive aneurysmal dilatation of a depopulated ureteric hemodialysis xenograft.Hemodial Int.2009; 13(1): 3–5.
35.
SparkJ.I., YeluriS., DerhamC., WongY.T., LeitchD.. Incomplete cellular depopulation may explain the high failure rate of bovine ureteric grafts.Br J Surg.2008; 95(5): 582–585.
36.
SparksC.H.. Silicone mandril method for growing reinforced autogenous femoro-popliteal artery grafts in situ.Ann Surg.1973; 177(3): 293–300.
37.
HallinR.W.. Complications with the mandril-grown (Sparks) dacron arterial graft.Am Surg.1975; 41(9): 550–554.
38.
Shin'okaT., ImaiY., IkadaY., Shin'okaT.. Transplantation of a tissue-engineered pulmonary artery.N Engl J Med.2001; 344(7): 532–533.
39.
Shin'okaT., MatsumuraG., HibinoN.. Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells.J Thorac Cardiovasc Surg.2005; 129(6): 1330–1338.
40.
SolettiL., HongY., GuanJ.. A bilayered elastomeric scaffold for tissue engineering of small diameter vascular grafts.Acta Biomater.2010; 6(1): 110–122.
41.
HiraiJ., MatsudaT.. Venous reconstruction using hybrid vascular tissue composed of vascular cells and collagen: tissue regeneration process.Cell Transplant.1996; 5(1): 93–105.
CampbellJ.H., EfendyJ.L., CampbellG.R.. Novel vascular graft grown within recipient's own peritoneal cavity.Circ Res.1999; 85(12): 1173–1178.
44.
ChueW.L., CampbellG.R., CapliceN.. Dog peritoneal and pleural cavities as bioreactors to grow autologous vascular grafts.J Vasc Surg.2004; 39(4): 859–867.
45.
SakaiO., KandaK., Ishibashi-UedaH.. Development of the wing-attached rod for acceleration of “Biotube” vascular grafts fabrication in vivo.J Biomed Mater Res B: Appl Biomater.2007; 83(1): 240–247.
46.
PohM., BoyerM., SolanA.. Blood vessels engineered from human cells.Lancet.2005; 365(9477): 2122–2124.
47.
EnzlerM.A., RajmonT., LachatM., LargiadèrF.. Long-term function of vascular access for hemodialysis.Clin Transplant.1996; 10(6 Pt 1): 511–515.
48.
PalumboR., NiscolaP., CalabriaS.. Long-term favorable results by arteriovenous graft with Omniflow II prosthesis for hemodialysis.Nephron Clin Pract.2009; 113(2): c76–c80.
49.
GrabenwögerM., FitzalF., SiderJ.. Endothelialization of biosynthetic vascular prostheses after laser perforation.Ann Thorac Surg.1998; 66(6)(Suppl): S110–S114.
50.
WiltbergerG., MatiaI., SchmelzleM.. Mid- and long-term results after replacement of infected peripheral vascular prosthetic grafts with biosynthetic collagen prosthesis.J Cardiovasc Surg (Torino).2014; 55(5): 693–698.
51.
BhrugubandaV., HowellS., PatelK., ChoongA.. Omniflow® biosynthetic grafts: Current evidence for use in haemodialysis.Int J Surg.2013; 11(8): 744.
52.
KochG., GutschiS., PascherO., FruhwirthH., GlanzerH.. Analysis of 274 Omniflow Vascular Prostheses implanted over an eight-year period.Aust N Z J Surg.1997; 67(9): 637–639.
53.
McAllisterT.N., MaruszewskiM., GarridoS.A.. Effectiveness of haemodialysis access with an autologous tissue-engineered vascular graft: a multicentre cohort study.Lancet.2009; 373(9673): 1440–1446.
54.
WystrychowskiW., CierpkaL., ZagalskiK.. Case study: first implantation of a frozen, devitalized tissue-engineered vascular graft for urgent hemodialysis access.J Vasc Access.2011; 12(1): 67–70.
55.
PeckM.K., DusserreN., ZagalskiK.. New biological solutions for hemodialysis access.J Vasc Access.2011; 12(3): 185–192.
56.
DemberL.M., BeckG.J., AllonM.; Dialysis Access Consortium Study Group. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.JAMA.2008; 299(18): 2164–2171.
